ReviewIndian journal of clinical biochemistry : IJCB2016
Apolipoprotein A-I: A Molecule of Diverse Function.
Review in Indian journal of clinical biochemistry : IJCB, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 4 syntheses or guidelines pooled it, 138 citations in OpenAlex.
- Blood Lipid Levels in Response to Almond Consumption: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Nutrients · 2025Pooled it
- Evaluation of common protein biomarkers involved in the pathogenesis of respiratory diseases with proteomic methods: A systematic review.Immunity, inflammation and disease · 2023Pooled it
- Pooled it
- Prognostic Significance of Pretreatment Apolipoprotein A-I as a Noninvasive Biomarker in Cancer Survivors: A Meta-Analysis.Disease markers · 2018Pooled it
- Plasma proteins associated with circulating carotenoids in Nepalese school-aged children.Archives of biochemistry and biophysics · 2018Trial
- Microplastics negatively impact ecosystems, human health and cellular proteostasis.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2026Review
- Apolipoprotein A-I (CSL112) and Cardiovascular Outcomes in Atherosclerotic Cardiovascular Disease: A Scoping Review.Clinical cardiology · 2026Article
- A narrative review of impacts of apolipoproteins on atherosclerotic coronary plaques.NPJ cardiovascular health · 2026Review
- The Impact of Modern Industrialized Dietary Sodium Intake on the Plasma Proteome.American journal of hypertension · 2026Article
- ApoA1-driven cholesterol efflux and macrophage polarization orchestrate T-cell differentiation towards controlling Leishmania donovani pathogenesis.Scientific reports · 2025Article
- Apolipoprotein A-I: a non-negligible marker in hypertriglyceridemia-induced acute pancreatitis.European journal of medical research · 2025Article
- Plasma apolipoprotein A-I is a causal protective factor in sepsis.Scientific reports · 2025Article
- Construction and validation of HBV-ACLF bacterial infection diagnosis model based on machine learning.BMC infectious diseases · 2025Article
- Causal Relationship Between Blood Metabolites and Osteoporosis: A Two-Sample Mendelian Randomization and Genetic Correlation Analysis.Bioengineering (Basel, Switzerland) · 2025Article
- Identification, characterization, and anti-inflammatory activity of a lipocalin-like protein cloned fromFood science and biotechnology · 2025Article
- Serum Apolipoprotein B and B/A1 Ratio as Early Negative Biomarkers for OCT- and OCTA-Detected Retinal Changes in Diabetic Macular Edema.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Assessment of lipid profile and its association with acne vulgaris severity in adolescents and young adults: A cross-sectional study in Kurdistan Region, Iraq.Qatar medical journal · 2025Article
- The Potential Causal Association of Apolipoprotein A and B and Age-Related Macular Degeneration: A Mendelian Randomisation Study.Biomedicines · 2024Article
- Top-Down Proteomics Identifies Plasma Proteoform Signatures of Liver Cirrhosis Progression.Molecular & cellular proteomics : MCP · 2024Article
- Blood lipid profiles as a prognostic biomarker in idiopathic pulmonary fibrosis.Respiratory research · 2024Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apolipoprotein A-I (apo A-I) an indispensable component and a major structural protein of high-density lipoprotein (HDL), plays a vital role in reverse cholesterol transport and cellular cholesterol homeostasis since its identification. Its multifunctional role in immunity, inflammation, apoptosis, viral, bacterial infection etc. has crossed its boundary of its potential of protecting cardiovascular system and lowering cardiovascular disease risk, attributing HDL to be known as a protective fat removal particle. Its structural homology with prostacyclin stabilization factor has contributed to its anti-clotting and anti-aggregatory effect on platelet which has potentiated its cardio-protective role as well as its therapeutic efficacy against Alzheimer's disease. The binding affinity and neutralising action against endotoxin lipopolysaccharide, reduces the toxic manifestations of septic shock. As a negative acute phase protein, it blocks T-cell signalling of macrophages. However the recently identified anti-tumor activity of apo A-I has been highlighted in various models of melanoma, lung cancer, ovarian cancer, lymphoblastic leukaemia, gastric as well as pancreatic cancers. These cancer fighting effects are directed towards regression of tumor size and distant metastasis by its immuno modulatory activity as well as its clearing effect on serum lysophospholipids. This lowering effect on lysophospholipid concentration is utilized by apo A-I mimetic peptides to be used in retarding tumor cell proliferation and as a potential cancer therapeutic agent. Not only that, it inhibits the tumor associated neo-angiogenesis as well as brings down the matrix degrading enzymes associated with tumor metastasis. However this efficient therapeutic potential of apo A-I as an anti tumor agent awaits further future experimental studies in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.